Fragmented and inefficient research funding means Australia is not tackling the deadliest forms of cancer, say a coalition of charities and funding bodies seeking an overhaul of the sector.
A paper launched today by the Cancer Research Leadership Forum (CRLF) says the $300 million research investment regime is disjointed and limited by “unnecessary competition, duplication, inefficiencies and gaps”.
Some cancers, such as those of the breast, cervix, ovary and skin received over-generous funding compared to the amount of death they caused, said Carole Renouf, the chief executive of the National Breast Cancer Foundation, who also piloted the paper.
Lung cancer, responsible for around 20% of Australian cancer deaths, receives only one percent of funding.
Discrepancies were mainly down to certain cancers having much higher...
This site is intended for Registered Medical Practitioners.
To make the most of Oncology Update, you need to be logged in.